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Summary
Background Innovative approaches are required for leprosy control to reduce cases and curb transmission of 
Mycobacterium leprae. Early case detection, contact screening, and chemoprophylaxis are the most promising tools. 
We aimed to generate evidence on the feasibility of integrating contact tracing and administration of single-dose 
rifampicin (SDR) into routine leprosy control activities.
Methods The leprosy post-exposure prophylaxis (LPEP) programme was an international, multicentre feasibility 
study implemented within the leprosy control programmes of Brazil, India, Indonesia, Myanmar, Nepal, Sri Lanka, 
and Tanzania. LPEP explored the feasibility of combining three key interventions: systematically tracing contacts of 
individuals newly diagnosed with leprosy; screening the traced contacts for leprosy; and administering SDR to eligible 
contacts. Outcomes were assessed in terms of number of contacts traced, screened, and SDR administration rates. 
Findings Between Jan 1, 2015, and Aug 1, 2019, LPEP enrolled 9170 index patients and listed 179 769 contacts, of 
whom 174 782 (97·2%) were successfully traced and screened. Of those screened, 22 854 (13·1%) were excluded from 
SDR mainly because of health reasons and age. Among those excluded, 810 were confirmed as new patients (46 per 
10 000 contacts screened). Among the eligible screened contacts, 1182 (0·7%) refused prophylactic treatment with 
SDR. Overall, SDR was administered to 151 928 (86·9%) screened contacts. No serious adverse events were reported.
Interpretation Post-exposure prophylaxis with SDR is safe; can be integrated into different leprosy control programmes 
with minimal additional efforts once contact tracing has been established; and is generally well accepted by index 
patients, their contacts, and health-care workers. The programme has also invigorated local leprosy control through 
the availability of a prophylactic intervention; therefore, we recommend rolling out SDR in all settings where contact 
tracing and screening have been established. 
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Introduction
Leprosy is a chronic infectious disease caused by 
Mycobacterium leprae. The clinical manifestations are 
largely confined to the skin, peripheral nervous system, 
eyes, and upper respiratory tract. M leprae predominantly 
affects peripheral nerves and immunologically mediated 
reactions can cause nerve damage in the face, arms, and 
legs, often resulting in disability, which in turn can lead 
to stigma and social exclusion. Over the past decade, 
the annual number of new leprosy cases reported to 
WHO has plateaued at slightly more than 200 000 patients, 
from nearly 150 countries.1 Leprosy is a neglected disease 
with poor awareness among both the public and medical 
practitioners. Innovation is needed to enhance the 
effectiveness of leprosy control by improving early case 
detection and reducing the risk of infection and disease 
among those most at risk.2 The ultimate goal is to reduce 
morbidity and to interrupt transmission of M leprae 
between humans.3 Consequently, WHO’s Global Leprosy 
Strategy 2016–20 identified early case detection and 
targeted case finding among high-risk groups as key 
strategic operational components.4 Although both early 
case detection and targeted case finding can make an 
impact, additional interventions are needed to interrupt 
transmission. No leprosy-specific immuno prophylactic 
intervention is available. Although BCG vaccination 
confers some level of protection,5 no vaccine on the 
market specifically targets M leprae.6 The most effective 
approach to reducing the risk of developing leprosy 
among individuals exposed to M leprae over extended 
periods is chemoprophylaxis, usually given to close 
contacts of individuals who have been diagnosed with 
leprosy within the past 3 months.7–9
The idea of chemoprophylaxis in leprosy is not 
new. In the 1960s and 1970s, trials were done in India 
and Uganda with dapsone administered as chemo-
prophylaxis,10–14 subsequently followed by trials with 
acedapsone in India.15,16 A meta-analysis indicated an 
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overall reduction in the risk of developing leprosy among 
contacts of up to 50%.17 In 1988, a chemo prophylaxis study 
with single-dose rifampicin (SDR) was implemented in 
the Southern Marquesas Islands; this trial was not 
controlled. After 10 years, findings suggested an effective-
ness of SDR of 35–40%.18–20 Due to the high leprosy 
incidence in the Pacific islands, chemoprophylaxis 
programmes were also done in the Federated States 
of Micronesia, Kiribati, and Marshall Islands in the 
mid-1990s.21 Rifampicin–ofloxacin–minocycline was given 
to adults (aged ≥15 years) and rifampicin only to children 
younger than 15 years.22 By 1999, a substantial reduction in 
case detection rates was observed, but the latest figures 
from 2016 indicate that this reduction was not sustained.1 
In 2000, a chemoprophylaxis intervention study with 
rifampicin was started on five Indonesian islands where 
leprosy is highly endemic.23,24 Two types of intervention 
strategies were compared with a control group. The 
blanket (complete population) group included three 
islands on which prophylaxis was given to all eligible 
individuals. The contact group included an island on 
which prophylaxis was given to all eligible contacts of all 
known and newly diagnosed individuals with leprosy. The 
control group was the population of an island to which no 
chemoprophylaxis was offered. This study showed that 
population-based chemoprophylaxis was associated with a 
reduced leprosy incidence in the first 3 years after 
implementation. The answer to the need for a more 
rigorous trial to establish the preventive efficacy 
of SDR as post-exposure chemoprophylaxis was the 
COLEP study in Bangladesh, a single-centre, double-blind, 
cluster randomised, placebo-controlled trial. SDR given to 
contacts of individuals with newly diagnosed leprosy 
resulted in an overall reduction in incidence of leprosy of 
57%.7 The efficacy of SDR depended on contact level. Some 
subgroups appeared to respond well to SDR, such as 
people who were not blood relatives and neighbours 
of neighbours and (other) social contacts, with protection 
up to around 70%. One particular subgroup, however, 
namely blood relatives (ie, parents, children, and siblings) 
responded less effectively to SDR (24% protection). The 
BCG vaccination status of the contact was also important.25 
If the contact had received the BCG vaccination as part of a 
childhood vaccination programme (as established by the 
presence of a BCG scar), the protective effect of SDR was 
80%. The SDR treatment group reached the background 
level of the general population at 2 years, while the placebo 
group reached this level at 4 years. At 4 years and 6 years of 
follow-up, there were no longer differences between 
treatment and placebo groups.26,27
Research in context
Evidence before this study
The evidence for this international feasibility programme was 
summarised by WHO as part of their guideline development 
process for leprosy, published in 2018. These evidence-based 
recommendations used guideline development methods based 
on the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) approach. GRADE includes an 
assessment of quality of evidence (high, moderate, low, or very 
low), consideration of the overall balance of benefits to harms 
(at individual and population levels), patient or health worker 
values and preferences, resource use, effects on equity, cost–
effectiveness, and consideration of feasibility and effectiveness 
across various settings, including resource-limited settings and 
those in which access to laboratory infrastructure and 
specialised tests is poor. The quality of evidence for post-
exposure prophylaxis with single-dose rifampicin (SDR) in 
leprosy was considered moderate. The most authoritative study 
was a large single-centre, double-blind, cluster-randomised, 
placebo-controlled trial to establish the preventive efficacy of 
SDR as post-exposure chemoprophylaxis in leprosy. In this trial, 
SDR given to contacts of individuals with newly diagnosed 
leprosy resulted in an overall reduction in incidence of leprosy of 
57%, and reduced the incidence of leprosy among the contacts 
to the level of the general population in the area within 2 years. 
The WHO Guidelines for the Diagnosis, Treatment and 
Prevention of leprosy suggested that to prevent leprosy in 
healthy close contacts of patients with leprosy, SDR should be 
administered if the contacts were aged 2 years or older, both 
leprosy and tuberculosis have been ruled out, and in the absence 
of other contraindications.
Added value of this study
This large-scale feasibility study in seven leprosy-endemic 
countries provides evidence that post-exposure prophylaxis 
with SDR is safe; can be integrated into different leprosy control 
programmes with minimal additional efforts once contact 
tracing has been established; and is generally well accepted by 
index patients, their contacts, and health-care workers. The 
programme has also been shown to invigorate local leprosy 
control through the availability of a prophylactic intervention.
Implications of all the available evidence
Implementation of post-exposure prophylaxis with SDR should 
be integrated in all leprosy-endemic countries as part of their 
routine leprosy control programme. In fact, India, Indonesia, 
and Nepal have already started this integration at a local scale, 
and are planning national roll-out as resources permit. Further 
research should focus on the optimal number of contacts to be 
included, which probably depends on the local epidemiological 
situation (eg, endemicity level and ratio of multibacillary to 
paucibacillary patients), household size, and health system 
characteristics. Also, alternative and possibly more effective 
prophylactic regimens should be investigated. Finally, the 
development of suitable field-friendly diagnostic tests for 
subclinical infection can help establish those contacts who 
would benefit most from post-exposure prophylaxis.
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In 2018, based on the available evidence, WHO 
included a recommendation to implement chemo-
prophylaxis with SDR for adult and child (aged 2 years 
and older) contacts of patients with leprosy, after 
excluding leprosy and tuberculosis disease, and in the 
absence of other contraindications in their Guidelines 
for the Diagnosis, Treatment and Prevention of Leprosy.28 
Yet evidence on the feasibility of integrating contact 
tracing with SDR administration into routine leprosy 
control activities was required by the WHO Global 
Leprosy Programme and national health authorities to 
assess the benefits, costs, and risks of such interventions.4 
Feasibility data collected from the field would position 
programme managers to more easily take informed 
decisions on the introduction of contact tracing combined 
with SDR administration as a new routine into their 
national strategic plans for leprosy control.29 To generate 
such evidence and explore the potential of the inter-
vention under various epidemiological, cultural, and 
health system conditions, the comprehensive leprosy 
post-exposure prophylaxis (LPEP) programme was 
established in 2014, with implementation starting in 2015 
in most sites.30
Here, we provide the main results of the LPEP 
feasibility study in seven countries participating in the 
programme. We aimed to generate evidence on the 
feasibility of integrating contact tracing and SDR 
administration into routine leprosy control activities. 
Methods
Study design and participants
The LPEP programme was an international, multicentre 
feasibility study implemented within the leprosy control 
programmes of Brazil, India, Indonesia, Myanmar, 
Nepal, Sri Lanka, and Tanzania. LPEP explored the 
feasibility and impact of combining three key inter-
ventions: (1) to systematically trace the contacts of 
individuals newly diagnosed with leprosy; (2) to screen 
the traced contacts for signs of the disease; and (3) to 
administer SDR as post-exposure prophylaxis to eligible 
contacts. The activities were implemented through the 
established structures of national leprosy control pro-
grammes. The aim of this study was to generate evidence 
and explore the feasibility of the intervention package to 
improve leprosy case finding among contacts of index 
patients and thus enhance early case detection and reduce 
the risk of developing leprosy among contacts.30 The 
intervention package was based on available evidence, 
most notably the benefits of contact tracing31,32 and the 
results of the efficacy of SDR in the COLEP trial.7,33 It 
combined these technical solutions with locally adapted 
strategies to deploy them under varying programme 
conditions and sociocultural contexts. The LPEP 
programme was not designed to establish efficacy of SDR 
and the study duration (approximately 3 years) was too 
short to establish epidemiological effect. Nevertheless, we 
have explored the potential effect of SDR in the LPEP 
areas through mathematical modelling and will report on 
this separately in future.
The basic protocol of the LPEP intervention was similar 
in all participating countries. The intervention was piloted 
in administrative units of the health system purposively 
selected based on the following criteria: a sufficiently high 
new case detection rate to achieve the calculated sample 
size; accessibility; and basic leprosy control infrastructure. 
The main characteristics of the selected districts have 
been described previously for six countries.30 In Brazil, 
four study sites were included, namely one in Pernambuco 
with a mean of 319 new patients over the 5 years before 
the study, one in Tocantins (n=847), and two in Mato 
Grosso (n=214 and n=136). Individuals with leprosy 
diagnosed within a defined period before the start of the 
field work and throughout a 3-year implementation 
interval were invited by local health-care staff or by trained 
volunteers to participate in the study. In the absence of 
relevant routine leprosy programme regulations, written 
or oral informed consent from index patients was required 
to disclose their disease status to their contacts who were 
then traced and screened for signs and symptoms of 
leprosy disease. Contacts without any evidence of leprosy 
were assessed for their eligibility to receive SDR. Those 
identified with signs of active leprosy were evaluated 
according to the routine leprosy control programme 
procedures and, if the diagnosis was confirmed, received 
multidrug therapy (MDT). No incentives were paid to 
patients, contacts, health-care staff, or volunteers, but field 
workers were entitled to reimbursement of costs associa-
ted with contact tracing. Country-specific LPEP protocol 
adaptations refer to the retrospective contact tracing 
period (typically 1–2 years), the contact definition (house-
hold, neighbours, social), and the minimal age for SDR 
eligibility (2 years vs 6 years). In Sri Lanka and Tanzania, 
only household contacts were targeted. In Myanmar, only 
household and neighbour contacts were targeted, with 
neighbours defined as inhabitants of houses in the 
immediate vicinity. In all other countries, household, 
neighbour, and social contacts were targeted. Social 
contacts could include other relevant contacts, such as 
classmates.
Also, the approach for screening differed between 
countries, with Indonesia applying a self-screening 
protocol whereby contacts received simple pictorial and 
text aids to detect leprosy and then self-identified if they 
or their family members had detected possible signs of 
leprosy disease on their bodies. Those who showed 
possible signs of leprosy were then screened by health-
care workers to confirm or exclude the presence of 
leprosy.34 Subsequently, contact screening procedures 
and SDR-PEP admini stration followed the same 
inclusion and exclusion criteria. An important difference 
is that a higher number of contacts could be included. In 
other countries, nurses, midwives, community health-
care workers, or volunteers were responsible for the 
screening effort. In Brazil, in accordance with routine 
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leprosy control programme procedures, BCG vaccination 
was offered as prophylaxis to contacts who had not 
previously received BCG as established by the absence of 
two BCG scars. Additionally, in accordance with local 
routine practices, contact tracing and screening were 
done anonymously, without disclosure of the index 
patient. Therefore, no informed consent was taken from 
the index patients in Brazil, but consent was still 
required from contacts before SDR administration.
Urine discolouration is a common side-effect of 
rifampicin and this factor was mentioned actively when 
seeking informed consent from participants. Reported 
urine colour changes were not considered as adverse 
events requiring follow-up. Leprosy control programmes 
were encouraged to report and investigate other adverse 
events potentially related to SDR, both through the 
provision of a LPEP-specific reporting form and through 
regular reminders during monitoring visits.
In all participating countries in which chemoprophylaxis 
had not yet been included in the list of standard 
interventions for leprosy control, clearance for the study 
was obtained from the competent ethical review 
committees.
Procedures
The strategic document underlying the LPEP protocol 
was developed by NLR and Novartis Foundation in close 
collaboration with other international partners and in 
consultation with national leprosy control programme 
representatives.30 Based on the strategic document, 
country LPEP protocols were defined by the leprosy 
control programmes of the participating countries, in 
close collaboration with their designated International 
Federation of Anti-Leprosy Association partners.34 
Cambodia also participated in the LPEP programme, but 
followed a modified protocol and timelines owing to 
distinct health system and epidemio logical conditions.35,36 
Consequently, the results pertaining to Cambodia will be 
published separately.
The national leprosy control programmes with their 
established partners including non-governmental organi-
sations and volunteers implemented the study field work. 
Two academic partners determined the minimal sample 
size needed to show the effect of the intervention, 
developed the data recording and reporting system, did 
quality assurance missions throughout the implemen-
tation period in close coordination with International 
Federation of Anti-Leprosy Association partners and 
leprosy control programme managers, and supported 
data analysis and results dissemination. Quality assurance 
focused on protocol adherence, completeness of contact 
tracing and quality of contact screening, and integrity of 
the data collection and reporting. A steering committee 
representing independent academic advisers, leprosy 
experts, and observers from the WHO Global Leprosy 
Programme in addition to key LPEP programme 
stakeholders provided strategic guidance. 
The data recording and reporting system was adapted to 
local conditions to minimise duplication with the routine 
leprosy programme documentation, align reporting 
channels, and accommodate preferred data entry locations. 
The data collection documenting the activities focused on 
the individual characteristics of the index patients and 
their contacts, and the reasons for exclusion at every stage 
of the process to provide data for the coverage achievable 
in different settings. Other variables of interest included 
the number of new patients with leprosy identified in the 
frame of the field work. Data were regularly shared with 
the academic partners and analysed at least once a year. 
Interim and final results were shared with all partners as 
part of the annual LPEP meetings and final dissemination 
workshops in the participating countries.
As part of the programme design process, the risk of 
introducing rifampicin resistance in Mycobacterium 
tuberculosis by providing SDR was formally assessed. 
The conclusion of the literature study and expert 
consultation focusing on this topic was that the risk 
of inducing resistance is negligible.37 Key experts partici-
pating in the consultation were not otherwise linked to 
the LPEP programme. As a precaution and as suggested 
in the  expert consultation, screening for signs of 
active tuberculosis was implemented so SDR was only 
given to contacts without suggestive symptoms, and 
patients suspected to have tuberculosis were referred 
for full evaluation and appropriate treatment. Extending 
the argumentation on risk of inducing resistance 
from M tuberculosis to M leprae, the expert group again 
concluded that it is highly improbable that the develop-
ment of resistant mutants would be encouraged by SDR 
administration. Importantly, all potential SDR recipients 
were screened for signs of leprosy, and confirmed 
patients received standard MDT in line with national 
leprosy treatment protocols.
Integral parts of the LPEP programme were side 
studies to establish feasibility,38 effect on perceptions 
of leprosy and acceptability of the intervention,39,40 and 
health system and health economic parameters in 
different contexts.34,41
Role of the funding source
Novartis Foundation and International Federation of 
Anti-Leprosy Association partners provided technical 
input in the design phase of the LPEP programme 
and ensured overall programme coordination. Novartis 
Foundation funded most of the programme activities and 
ensured central coordination. The funder had no role 
in data interpretation or the decision to submit for 
publication. JHR and PS had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication. 
Results
Field work related to the LPEP programme started in a 
stepwise arrangement in six countries from Jan 1 to 
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March 1, 2015, followed by Brazil in 2016. Within a 
3-year period, index patients diagnosed since Jan 1, 2013 
(India, Nepal), Jan 1, 2014 (Myanmar, Tanzania), or Jan 
1, 2015 (Brazil, Indonesia, Sri Lanka) were approached 
for inclusion in the study. The number of new patients 
with leprosy registered in the project districts across 
the seven countries was 10 203, ranging from 540 
(Myanmar) to 2669 (Brazil; table 1). The profiles of the 
country index patient cohorts differed markedly: the 
rate of multi bacillary leprosy among the index patients 
varied between 28·9% (India) and 80·8% (Tanzania), 
the grade 2 disability rate was between 1·8% (Nepal) 
and 17·4% (Myanmar), and the proportion of girls and 
women was between 38·6% (Sri Lanka) and 53·7% 
(India). Finally, between 3·9% (Tanzania) and 21·8% 
(India) of the index patients were aged younger than 
15 years (table 1).
Between Jan 1, 2015, and Aug 1, 2019, overall, 
9170 (89·9%) of the 10 203 registered index patients 
were enrolled for participation in the study (table 1). 
In Sri Lanka, patients who were not enrolled were not 
registered, so these numbers are not available. Main 
reasons for not enrolling index patients were living 
outside of the LPEP district, absence of contacts according 
to the local contact definition, and unstated reasons. The 
profiles of registered and enrolled index patients in terms 
of proportion of multibacillary cases, grade 2 disability, 
sex, and children are similar. Approximately 1% of 
Brazil India Indonesia Myanmar Nepal Sri Lanka Tanzania Total
Total listed contacts* 24 219 43 305 40 517 9520 54 346 1968 5894 179 769
Listed contacts per enrolled index patient 12 26 37 19 23 2 10 20
Not screened 2444 (10·1%) 972 (2·2%) 350 (0·9%) 80 (0·8%) 494 (0·9) 560 (28·5%) 87 (1·5%) 4987 (2·8%)
Total screened 21 775 42 333 40 167 9440 53 852 1408 5807 174 782 (97·2%)
Reason for exclusion from single-dose rifampicin administration†
Possible tuberculosis 0 1 39 21 29 2 3 ··
Pregnancy 72 195 110 90 122 9 99 ··
Other medical reason 1758 1624 563 399 1055 166 750 ··
Other reason‡ 1652§ 10 078 0 38 1961 4 2 ··
Suspected leprosy NA 141 207 15 273 46 310 ··
Refusal of single-dose rifampicin 1076 0 25 4 0 29 48 ··
Received single-dose rifampicin of total 
screened
17 217 (79·1%) 30 295 (71·6%) 39 279 (97·8%) 8873 (94·0%) 50 412 (93·6%) 1161 (82·5%) 4691 (80·8%) 151 928 (86·9%)
Data are n or n (%). Percentages provided for relevant indicators. NA=not applicable. *In Sri Lanka and Tanzania, only household contacts were targeted. In Myanmar, only household and neighbour contacts 
were targeted. In all other countries, household, neighbour, and social contacts were targeted. †Multiple mentions possible. ‡Including recent alcohol consumption and old age perceived as risk factor for 
single-dose rifampicin administration by the field team.  §Data not available to distinguish between exclusion due to other reasons or suspected leprosy.  
Table 2: Contacts of patients with leprosy enrolled and screened in the leprosy post-exposure prophylaxis programme districts by screening status and exclusion reason
Brazil India Indonesia Myanmar Nepal Sri Lanka Tanzania Total
Registered index patients 2669 1662 1197 540 2368 940 827 10 203
Multibacillary leprosy 1990 (74·6%) 481 (28·9%) 938 (78·4%) 392 (72·6%) 1275 (53·8%) 499 (53·1%) 668 (80·8%) 6243 (61·2%)
Grade 2 disability 138 (5·2%) 54 (3·2%) 45 (3·8%) 94 (17·4%) 43 (1·8%) 58 (6·2%) 30 (3·6%) 462 (4·5%)
Sex
Female 1210 (45·3%) 893 (53·7%) 593 (49·5%) 231 (42·8%) 1007 (42·5%) 363 (38·6%) 374 (45·2%) 4671 (45·8%)
Male 1459 (54·7%) 769 (46·3%) 604 (50·5%) 309 (57·2%) 1361 (57·5%) 577 (61·4%) 453 (54·8%) 5532 (54·2%)
Children younger than 15 years 146 (5·5%) 362 (21·8%) 93 (7·8%) 22 (4·1%) 198 (8·4%) 86 (9·1%) 32 (3·9%) 939 (9·2%)
Not enrolled index patients 670 (25·1%) 19 (1·1%) 106 (8·9%) 26 (4·8%) 0 0 212 (25·6%) 1033 (10·1%)
Enrolled index patients 1999 (74·9%) 1643 (98·9%) 1091 (91·1%) 514 (95·2%) 2368 (100%) 940 (100%) 615 (74·4%) 9170 (89·9%)
Multibacillary leprosy 1526 (76·3%) 472 (28·7%) 853 (78·2%) 374 (72·8%) 1275 (53·8%) 499 (53·1%) 480 (78·0%) 5479 (59·7%)
Grade 2 disability 103 (5·2%) 53 (3·2%) 38 (3·5%) 90 (17·5%) 43 (1·8%) 58 (6·2%) 28 (4·6%) 413 (4·5%)
Sex
Female 924 (46·2%) 887 (54·0%) 545 (50·0%) 222 (43·2%) 1007 (42·5%) 363 (38·6%) 299 (48·6%) 4247 (46·3%)
Male 1075 (53·8%) 756 (46·0%) 546 (50·0%) 292 (56·8%) 1361 (57·5%) 577 (61·4%) 316 (51·4%) 4923 (53·7%)
Children younger than 15 years 98 (4·9%) 360 (21·9%) 86 (7·9%) 20 (3·9%) 198 (8·4%) 86 (9·1%) 18 (2·9%) 866 (9·4%)
Data are n or n (%). Contact tracing was routinely implemented pre-leprosy post-exposure prophylaxis in Brazil, India, Indonesia, Myanmar, and Nepal (in Brazil and Myanmar only for household members). 
Contact tracing was not routinely implemented pre-leprosy post-exposure prophylaxis in Sri Lanka and Tanzania.  
Table 1: Patients with leprosy diagnosed in the leprosy post-exposure prophylaxis programme districts
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the index patient cohort (data not shown) refused the 
disclosure of their condition to contacts and thus could 
not be enrolled.
179 769 contacts were registered for the 9170 index 
patients enrolled in the study (table 2). In  Sri Lanka and 
Tanzania, where only household contacts were targeted, a 
mean of two contacts per index patient was listed for Sri 
Lanka and a mean of ten contacts per index patient was 
listed for Tanzania. In the other five countries, where 
neighbours (Myanmar) and social contacts (other 
countries) were also targeted, the mean number of 
contacts was 23 per index patient. The range in number 
of contacts per index patient was from 12 in Brazil to 37 in 
Indonesia. Among the listed contacts, 174 782 (97·2%) 
could be traced and screened. The remaining contacts 
(n=4987) were unavailable for screening. A stratification 
of the contacts by country, age group, and contact level 
(ie, household, neighbour, and social) is shown in table 3.
Among the 174 782 screened contacts, leprosy diagnosis 
was confirmed in 810 individuals (new case detection rate 
46 per 10 000; table 4). The highest rates of individuals 
with newly diagnosed leprosy among screened contacts 
were observed in Tanzania (160 per 10 000) and Brazil 
(141 of 10 000), while the lowest rate was in India 
(10 per 10 000). All individuals with newly diagnosed lep-
rosy were directly enrolled for MDT according to national 
leprosy treatment protocols. Of the 174 782 screened 
contacts, 22 854 (13·1%) were not eligible for SDR 
administration according to the exclusion criteria (table 2). 
Across the seven countries, 1182 contacts (0·7%; range 0% 
Brazil India Indonesia Myanmar Nepal Sri Lanka Tanzania Total
Total newly 
diagnosed*
308; NCDR 141 42; NCDR 10 98; NCDR 24 15; NCDR 16 244; NCDR 45 10; NCDR 71 93; NCDR 160 810
Younger than 
15 years†
21 (6·8%); NCDR 47 15 (35·7%); NCDR 11 NA 1 (6·7%); NCDR 4 34 (13·9%); NCDR 21 2 (20·0%); NCDR 46 14 (15·1%); NCDR 63 ··
Sex
Male 139 (45·1%) 20 (47·6%) NA 14 (93·3%) 130 (53·3%) 4 (40·0%) 53 (57·0%) ··
Female 169 (54·9%) 22 (52·4%) NA 1 (6·7%) 114 (46·7%) 6 (60·0%) 40 (43·0%) ··
Type of Leprosy
Paucibacillary 84 (27·3%) 37 (88·1%) NA 8 (53·3%) 177 (72·5%) NA NA ··
Multibacillary 224 (72·7%) 5 (11·9%) NA 7 (46·7%) 67 (27·5%) NA NA ··
Grade 2 disability 22 (7·1%) 0 NA 0 NA NA NA ··
Contact level‡
Household 56; NCDR 118 11; NCDR 11 15; NCDR 42 6; NCDR 30 86; NCDR 64 10; NCDR 71 93; NCDR 160 277
Neighbour 193; NCDR 154 27; NCDR 8 80; NCDR 22 9; NCDR 12 155; NCDR 39 ·· ·· ··
Social 59; NCDR 132 4; NCDR 112 3; NCDR 265 ·· 3; NCDR 74 ·· ·· ··
Data are n (%); NCDR or n (%). NA=data not available due to difficulties in linking leprosy registers to contact tracing and screening registers. NCDR=new case detection rate per 10 000. *The denominators of the 
NCDRs are shown in table 2 under total screened. †The denominators of the NCDRs are the sum of the age groups younger than 2 years or 6 years and aged 2–14 years or 6–14 years shown in table 3. ‡In Sri Lanka 
and Tanzania, only household contacts were targeted. In Myanmar, only household and neighbour contacts were targeted. In all other countries, household, neighbour, and social contacts were targeted. The 
denominators of these rates are shown in table 2 under contact level.  
Table 4: Newly diagnosed patients with leprosy among contacts screened in the leprosy post-exposure prophylaxis programme districts
Brazil India Indonesia Myanmar Nepal Sri Lanka Tanzania Total
Age, years
<2 or <6* 135 (0·6%) 563 (1·3%) 347 (0·9%) 249 (2·6%) 512 (1·0%) 34 (2·4%) 726 (12·5%) 2566 (1·5%)
2–14 or 
6–14*
4335 (20·2%) 13 231 (31·3%) 5986 (14·9%) 2162 (22·9%) 15 456 (28·7%) 404 (28·7%) 1481 (25·5%) 43 055 (24·7%)
15–24 3732 (17·4%) 9527 (22·5%) 5663 (14·1%) 1460 (15·5%) 10 861 (20·2%) 248 (17·6%) 1172 (20·2%) 32 663 (18·7%)
25–49 8608 (40·1%) 14 004 (33·1%) 16 406 (40·8%) 3420 (36·2%) 18 737 (34·8%) 480 (34·1%) 1714 (29·5%) 63 369 (36·3%)
≥50 4680 (21·8%) 5008 (11·8%) 11 765 (29·3%) 2149 (22·8%) 8286 (15·4%) 242 (17·2%) 714 (12·3%) 32 844 (18·8%)
Contact level†
Household 4737 (21·8%) 9625 (22·7%) 3533 (8·8%) 2018 (21·4%) 13 516 (25·1%) 1408 (100%) 5807 (100%) 40 644 (100%)
Neighbour 12 571 (57·7%) 32 351 (76·4%) 36 521 (90·9%) 7422 (78·6%) 39 933 (74·2%) ·· ·· ··
Social† 4467 (20·5%) 357 (0·8%) 113 (0·3%) ·· 403 (0·7%) ·· ·· ··
Data are n (%). *Sri Lanka and Tanzania set the lower age limit at 6 years, the other countries at 2 years. For Brazil, age information is missing for 285 contacts. †In Sri Lanka 
and Tanzania, only household contacts were targeted. In Myanmar, only household and neighbour contacts were targeted. In all other countries, household, neighbour, and 
social contacts were targeted. †Including classmates, co-workers, and residents in the same institution (eg, retirement home) as the index patient. 
Table 3: Contacts of patients with leprosy screened in the leprosy post-exposure prophylaxis programme districts by age and type of contact
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in Myanmar, Nepal, and Tanzania to 4·9% in Brazil) 
refused the prophylactic treatment with SDR. Overall, 
SDR was administered to 151 928 (86·9%) of the 
174 782 screened contacts (figure).
The data for characteristics of newly diagnosed patients 
with leprosy among the screened contacts regarding age, 
sex, type of leprosy, and grade 2 disability were not 
complete for four countries (Indonesia, Nepal, Sri Lanka, 
and Tanzania). Where available, these characteristics did 
not differ markedly from those of the index patient 
cohort in the same country including the high proportion 
of child patients in India and important differences 
in the proportion of multibacillary cases among the 
patient cohort. Table 4 also shows the new case detection 
rate per 10 000 among the contact categories. In some 
countries (Indonesia, Myanmar, Nepal), a gradient is 
seen with a higher rate among household contacts than 
the neighbour contacts, while a reverse trend is seen in 
Brazil. A very high new case detection rate among social 
contacts was observed in India, Indonesia, and Nepal 
compared with household contacts and neighbours. 
However, the underlying numbers are very low.
Across the 3-year period in seven countries, three 
instances of adverse events following SDR were reported, 
namely one from Brazil in which a person developed an 
allergic reaction to rifampicin following SDR admini-
stration, and two from Nepal with skin reactions. After 
investigation, the adverse events in Nepal were con-
sidered to be due to existing underlying health conditions 
unrelated to SDR administration. No serious adverse 
events were reported.
Discussion
The LPEP programme was implemented in seven leprosy-
endemic countries and showed that the approach of 
contact tracing followed by the provision of SDR is feasible 
as part of routine leprosy control programme activities. 
There was a high level of acceptance by patients and 
health-care staff of home-based or community-based 
contact screening and SDR administration across different 
sociocultural, epidemio logical, and health system settings, 
with the notable exception of Sri Lanka where both health-
care staff and patients preferred contact screening and 
SDR provision in health-care facilities rather than at 
home. Considerable efforts were necessary to implement 
contact tracing in settings where it had not previously 
been introduced into the routine control activities. This 
effort included the identification and training of field staff, 
formal supervision, and establishing the necessary docu-
mentation system, all integrated into existing leprosy 
control programme structures. Of crucial relevance was 
the management of logistics and documentation of 
contact tracing as well as training to boost and maintain 
the capacity of field workers to reliably detect suggestive 
signs of leprosy so that identified contacts could then be 
referred to trained medical personnel for confirmatory 
diagnosis. The documentation and training needs also 
highlight the requirement for quality control procedures 
to support the programme. By contrast, the administration 
of SDR was readily integrated into the field routines.
The main challenges with SDR management were that 
rifampicin was not registered for leprosy prevention by 
the regulatory authorities in all LPEP programme 
countries except Brazil, and that it was often restricted 
for use against tuberculosis and other clearly specified 
indications. Other issues included the need for liquid 
rifampicin formulations for young children aged 
2–5 years in countries that had decided to also provide 
chemo prophylaxis to this age group. Also, for young 
children and contacts who were underweight, scales 
were required to establish bodyweight for calculating 
the correct rifampicin dose. Furthermore, the directly 
observed administration of SDR to contacts of individuals 
newly diagnosed with leprosy and individuals initially 
suspected of having leprosy but in whom confirmative 
diagnosis proved negative, posed a challenge in settings 
in which field workers do not routinely visit the homes of 
patients with leprosy. SDR should be given to contacts 
no earlier than 1 month after initiation of MDT of 
the individual newly diagnosed with leprosy to avoid 
immediate re-infection, as patients are assumed to 
become non-infectious within 4 weeks of treatment start. 
Contacts suspected of having leprosy and who after final 
evaluation are confirmed of not having leprosy should be 
given SDR as soon as possible after this confirmation. 
Both scenarios require a member of the contact tracing 
team to return to the household or that the contact 
presents to an assigned health centre.
Acceptance of SDR was generally good and there was a 
smooth integration of chemoprophylaxis into contact 
tracing procedures. Nevertheless, it remains crucial that 
the approach to identifying contacts is carefully tailored 
to the local context. In some populations, there is a 
marked reluctance of index patients to disclose their 
Figure: Study profile
Registration, screening, and single-dose rifampicin administration to contacts 
of individuals with leprosy recruited into the leprosy post-exposure prophylaxis 
programme.
179 769 individuals enrolled
174 782 (97·2%) screened
4987 individuals excluded
Absent and other reasons
22 854 excluded
1182 refusal to take single-dose rifampicin
810 diagnosed with leprosy
151 928 (86·9%) given single-dose 
rifampicin
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disease status to neighbours and sometimes even to 
household members. In such situations, alternative 
approaches to contact tracing are needed, for which 
disclosure of the disease status of the index patient is not 
required. This alternative could be achieved by defining 
contact tracing perimeters around the index patient that 
cover more than just a few households, allowing the 
masking of the index patient’s identity and guarding 
confi dentiality. Community-wide screening, often termed 
blanket screening, has been explored as an option to 
achieve good coverage in highly endemic communities.23,38
Screening for signs of active tuberculosis took place as 
part of the LPEP intervention. In all but one country, 
individuals suspected to have tuberculosis were identified 
and referred for full evaluation and appropriate treat-
ment. In some countries, the numbers might be less 
than expected based on known endemicity of tuberculosis 
in the country. This finding can be due to the quality of 
screening and the local epidemiology of tuberculosis.
There is a need to balance the target number of contacts 
per index patient with the benefits expected in terms of 
leprosy prevention and burden reduction. It is probable 
that the incremental benefit of adding ever more distant 
contacts at one point becomes negative as resource needs 
for contact tracing are likely to increase almost linearly 
with the number of households and contacts traced and 
screened. The optimal number of contacts probably 
also depends on the local epidemiological situation (eg, 
endemicity level and multibacillary to paucibacillary 
ratio), household size, and health system characteristics, 
and remains to be determined by country or region. 
Implementing SDR at a nationwide scale is challenging 
as systematic contact tracing and screening in leprosy is 
not widely or consistently done in many countries. 
Screening can best be managed locally, taking into 
account local culture, geography, and infrastructure, and 
preferably integrated with other contact tracing activities, 
such as for tuberculosis. But once contact tracing is in 
place, the provision of SDR only slightly increases the 
complexity of the programme. Chemoprophylaxis with 
SDR was shown to be cost-effective in Bangladesh42 
and India.43 In India, it was shown that it is cost-effective 
in both the short (5 years) and long term (25 years), 
with benefits depending on the extent to which disability 
can be prevented.43 Chemoprophylaxis is an important 
cornerstone of a leprosy elimination scenario and its 
cost-effectiveness should also be considered carefully 
from this perspective.44
For the evaluation of the LPEP programme, high-
quality documentation of the field work was particularly 
important. National leprosy control programmes inte-
grating contact tracing, screening, and SDR into their 
routine activities will also need to document these 
activities. We have proposed a set of minimal essential 
data for contact tracing, screening, and SDR 
administration to be recorded locally and reported to 
national and ultimately international agencies.45
The detection of previously undiagnosed patients with 
leprosy, including child cases among the screened 
contacts, indicates ongoing transmission and insufficient 
capacity of the routine programme for early detection. 
The public health benefits of improved early case 
detection are evident, such as the inclusion of population 
groups, who are often under-represented due to stigma 
or restricted health system access (eg, women and 
children), and the deployment of an intervention to 
reduce the risk of developing leprosy among contacts. 
However, the strategy will only have a long-term effect 
if it is embedded in a robust passive case detection 
system, possibly complemented by focused active case 
detection approaches, because index patients need to be 
identified before contact tracing can follow-up on the 
individuals at risk in their vicinity.
An important positive effect of the intervention was the 
reported qualitative invigoration of local leprosy control 
efforts. This positive effect on morale and efforts was seen 
in all settings irrespective of whether contact tracing and 
screening had already been integrated into the routine 
activities before the LPEP programme, and was reported 
by staff at different levels, from the periphery to the central 
leprosy control programme coordination. The increased 
motivation was associated mainly with the availability of a 
preventive intervention that is easy to administer as well 
as strengthened training and supervision. A challenge in 
several countries was the scarcity of health-care staff with a 
good command of leprosy-related knowledge, particularly 
the capacity to diagnose leprosy with confidence.
On the basis of the findings available to date from 
screening nearly 180 000 contacts and administering 
SDR to more than 150 000 of them across seven 
countries, we concluded that post-exposure prophylaxis 
with SDR is safe; can be integrated into the routines of 
different leprosy control programmes; and is generally 
well accepted by index patients, their contacts, and the 
health-care workforce. Chemoprophylaxis by definition 
provides temporary protection because it reduces the 
bacterial load with use of antimicrobial agents. It does 
not induce lasting immunological protection in the way 
that immuno prophylaxis with vaccines would. Contacts 
receiving SDR were routinely informed about this factor 
in the LPEP programme and advised to seek medical 
care any time in the future if signs and symptoms 
suspected of leprosy appeared. Although SDR is effective 
for most contacts, it is less effective for a small but 
important group of close contacts with an increased risk 
of leprosy (eg, blood-related household contacts and 
close contacts of patients with multibacillary leprosy). 
Research is ongoing into enhanced post-exposure 
prophylaxis regimens for these close contacts. Besides 
the protective effect of post-exposure prophylaxis, the 
intervention also invigorated local leprosy control 
through the introduction or strengthening of contact 
tracing, increased motivation associated with the 
availability of an effective and well accepted preventive 
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medication, and more frequent training and supervision. 
Together, these effects have translated into an improved 
leprosy control programme implementation, quality, 
and documentation. Since 2018, WHO has included 
post-exposure prophylaxis with SDR in their guidelines 
for leprosy control28 and several countries (India, 
Indonesia, and Nepal) have already introduced or are 
preparing to introduce post-exposure prophylaxis with 
SDR in their national programmes and strategic plans, 
with roll-out planned as resources permit. 
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